文献速递肝病

失代偿期肝硬化新型预后生物标志物:系统评价与荟萃分析

Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.
PubMed 文献 · Gut · 2023-12-07

该系统评价与荟萃分析纳入103项研究、29种生物标志物、共31362例生物标志物患者,评估新型尿液和血液生物标志物预测失代偿期肝硬化患者90天死亡率的能力。汇总90天死亡率为0.27(95%CI 0.24至0.29)。预测90天死亡率的比值均值(RoM)最高为白细胞介素6(IL-6)(2.56,95%CI 2.39至2.74),其次为尿中性粒细胞明胶酶相关脂质运载蛋白(uNGAL)(2.42,95%CI 2.20至2.66)和和肽素(copeptin)(2.33,95%CI 2.17至2.50),均高于MELD(1.44,95%CI 1.42至1.46)。

要点

  • IL-6、uNGAL和和肽素预测90天死亡率的RoM均高于MELD。
  • 汇总90天死亡率为0.27(95%CI 0.24至0.29)。
  • 多数研究为住院患者前瞻性队列,中位Child-Pugh-Turcotte评分9分、MELD评分18分。

核心结论

  • 包括IL-6、uNGAL和和肽素在内的新型生物标志物可能较单独MELD改善失代偿期肝硬化患者的预后评估。

研究设计与样本

  • 系统评价与荟萃分析,纳入103项研究,报告29种不同生物标志物,共31362例生物标志物患者。
  • 多数研究为住院患者前瞻性队列,中位Child-Pugh-Turcotte评分为9分,中位MELD评分为18分。

主要发现

  • 汇总90天死亡率为0.27(95%CI 0.24至0.29)。
  • 预测90天死亡率的RoM最高为IL-6(2.56,95%CI 2.39至2.74)。
  • 其次为uNGAL(2.42,95%CI 2.20至2.66)和和肽素(2.33,95%CI 2.17至2.50)。
  • 上述RoM均高于MELD(1.44,95%CI 1.42至1.46)。

关键数值与推荐

  • 采用比值均值(RoM)作为关联度量评估预测强度,RoM>1意味着发生结局者的平均生物标志物水平高于未发生者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with decompensated cirrhosis experience high mortality rates. Current prognostic scores, including the model for end-stage liver disease (MELD), may underperform in settings other than in those they were initially developed. Novel biomarkers have been proposed to improve prognostication accuracy and even to predict development of complications. METHODS: We performed a systematic review and meta-analysis on novel urine and blood biomarkers and their ability to predict 90-day mortality in patients with decompensated cirrhosis. Secondary outcomes included 28-day and 1-year mortality, and development of acute-on-chronic liver failure, acute kidney injury and other complications. To overcome differences in units, temporal changes in assays and reporting heterogeneity, we used the ratio of means (RoM) as measure of association for assessing strength in predicting outcomes. An RoM>1 implies that the mean biomarker level is higher in those that develop the outcome than in those that do not. RESULTS: Of 6629 unique references, 103 were included, reporting on 29 different biomarkers, with a total of 31 362 biomarker patients. Most studies were prospective cohorts of hospitalised patients (median Child-Pugh-Turcotte score of 9 and MELD score of 18). The pooled 90-day mortality rate was 0.27 (95% CI 0.24 to 0.29). The RoM for predicting 90-day mortality was highest for interleukin 6 (IL-6) (2.56, 95% CI 2.39 to 2.74), followed by urinary neutrophil gelatinase-associated lipocalin (uNGAL) (2.42, 95% CI 2.20 to 2.66) and copeptin (2.33, 95% CI 2.17 to 2.50). These RoMs were all higher than for MELD (1.44, 95% CI 1.42 to 1.46). CONCLUSION: Novel biomarkers, including IL-6, uNGAL and copeptin, can probably improve prognostication of patients with decompensated cirrhosis compared with MELD alone.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Juanola A, Ma AT, de Wit K, et al. Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis. Gut. 2023. PMID: 37884354. doi:10.1136/gutjnl-2023-329923

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。